《大行報告》瑞銀:吸入式新冠疫苗料逐漸成主流 重申康希諾-B(06185.HK)「買入」評級看88元
上海今日(26日)起啟動吸入式新冠疫苗加強接種,該疫苗由康希諾-B(06185.HK)生產,並意味正式在內地開放接種。該款吸入式疫苗適用於18歲及以上沒基礎疾病人士,並於上月獲國家藥監局緊急使用授權批准。目前吸入式疫苗暫不用於基礎免疫接種。另據國家有關要求,上海市民目前僅需接種1劑次同源加強免疫或序貫加強免疫接種。
瑞銀發表研究報告,指未來吸入式新冠疫苗料成主流,因其直接在上呼吸道產生抗體,料逐漸取代注射式疫苗,因較少副作用及管理過程較為簡單。是次容許接種吸入式新冠疫苗,意味內地或短期重新啟動大規模接種運動,為未來後新冠逐漸正常化做好準備,瑞銀重申予康希諾「買入」評級,目標價88元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.